Celsion Appoints Senior Vice President Product Development
Celsion Appoints Senior Vice President Product Development
May 24, 2005
Celsion Appoints Senior Vice President Product DevelopmentColumbia, MD - May 24, 2004: CELSION CORPORATION (AMEX: CLN) today announced that it has appointed Dr. David J. Braitman as Senior Vice President, Product Development. Dr. Braitman joins Celsion from his former position as Vice President, Clinical Research & Managing Director of the U.S. affiliate of Medisearch International Corporation, a European Clinical Research Organization. After a distinguished career in the U.S. Army Medical Research and Development Command, Dr. Braitman held senior development positions with Baxter Healthcare Corporation, Guildford Pharmaceuticals, Inc. and Quintiles, Inc.
Tony Deasey, Celsion's Chief Operating Officer, said, "We are delighted that David has joined the Celsion team. David has extensive experience both in drug research and development and the clinical and regulatory processes required to obtain approval for medical products in the United States. As Celsion expands into pharmaceuticals, David's experience in the management of development programs and his knowledge of the regulatory environment will be a substantial asset to the corporation."
Dr. Braitman is a graduate of the Hunter College and obtained his PhD and MS from University of Connecticut. After completing a Post Doctoral Fellowship at the National Institutes of Health he completed his M.H.S. at The Johns Hopkins University. Dr. Braitman is Diplomate of the American Board of Toxicology.
Tony Deasey, Celsion's Chief Operating Officer, said, "We are delighted that David has joined the Celsion team. David has extensive experience both in drug research and development and the clinical and regulatory processes required to obtain approval for medical products in the United States. As Celsion expands into pharmaceuticals, David's experience in the management of development programs and his knowledge of the regulatory environment will be a substantial asset to the corporation."
Dr. Braitman is a graduate of the Hunter College and obtained his PhD and MS from University of Connecticut. After completing a Post Doctoral Fellowship at the National Institutes of Health he completed his M.H.S. at The Johns Hopkins University. Dr. Braitman is Diplomate of the American Board of Toxicology.
